CELZ (Creative Medical Technology Holdings) WACC %:9.21% (As of Jun. 30, 2026) — 66% Below Median


CELZ Creative Medical Technology Holdings Inc CELZ
34 GF Score
Price $0.81
GF Value $0.32
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Creative Medical Technology Holdings WACC %?

Creative Medical Technology Holdings CELZ -32.48% 34 WACC % is 9.21% as of Jun. 30, 2026, which is 66% below its 10-year median of 27.20. GuruFocus rates CELZ with a GF Score™ of 34/100 and a GF Value™ of $0.32 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,425 Biotechnology companies, Creative Medical Technology Holdings ranks better than 56% on this metric.

As of today (2026-06-30), Creative Medical Technology Holdings's weighted average cost of capital is 9.21%%. Creative Medical Technology Holdings's ROIC % is -1344.95% (calculated using TTM income statement data). Creative Medical Technology Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


Creative Medical Technology Holdings  (NAS:CELZ) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Creative Medical Technology Holdings's weighted average cost of capital is 9.21%%. Creative Medical Technology Holdings's ROIC % is -1344.95% (calculated using TTM income statement data). Creative Medical Technology Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Creative Medical Technology Holdings WACC % Historical Data

* Premium members only.

The historical data trend for Creative Medical Technology Holdings's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creative Medical Technology Holdings WACC % Chart

Creative Medical Technology Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
WACC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.96 43.27 17.37 15.31 11.71

Creative Medical Technology Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.44 11.68 9.76 11.71 8.20

CELZ vs FBLG, GLMD, ALZN: WACC % Comparison

For the Biotechnology subindustry, Creative Medical Technology Holdings's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Creative Medical Technology Holdings WACC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Creative Medical Technology Holdings's WACC % distribution charts can be found below:

* The bar in red indicates where Creative Medical Technology Holdings's WACC % falls into.


CELZ
34GF Score
Creative Medical Technology Holdings Inc CELZ
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Creative Medical Technology Holdings WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Creative Medical Technology Holdings's market capitalization (E) is $2.995 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Creative Medical Technology Holdings's latest one-year quarterly average Book Value of Debt (D) is $0 Mil.
a) weight of equity = E / (E + D) = 2.995 / (2.995 + 0) = 1
b) weight of debt = D / (E + D) = 0 / (2.995 + 0) = 0

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.371%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Creative Medical Technology Holdings's beta is 0.8062.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.371% + 0.8062 * 6% = 9.2082%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2026, Creative Medical Technology Holdings's interest expense (positive number) was $-0 Mil. Its total Book Value of Debt (D) is $0 Mil.
Cost of Debt = -0 / 0 = %.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -5.761 = 0%.

Creative Medical Technology Holdings's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=1*9.2082%+0*%*(1 - 0%)
=9.21%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 9.21% mean?
Creative Medical Technology Holdings (CELZ) has a WACC % of 9.21% as of Jun. 30, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Creative Medical Technology Holdings and its competitors. This is 66% below median its historical median of 27.20. According to the industry distribution chart, Creative Medical Technology Holdings ranks #627 out of 1425 companies in the Biotechnology industry, placing it in the top 44%.
Is Creative Medical Technology Holdings' WACC % too high?
Creative Medical Technology Holdings' current WACC % of 9.21% is 66% below median its 10-year median of 27.20. The Biotechnology industry median WACC % is 9.99. Creative Medical Technology Holdings' value of 9.21% is 7.8% below this industry median. Based on the distribution chart, Creative Medical Technology Holdings ranks #627 out of 1425 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Creative Medical Technology Holdings has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' WACC % compare to FBLG and GLMD?
According to the Biotechnology industry distribution chart, Creative Medical Technology Holdings ranks #627 out of 1425 companies for WACC %. This puts Creative Medical Technology Holdings in the upper half of its industry. The industry median WACC % is 9.99. Creative Medical Technology Holdings' value of 9.21% is 7.8% below this benchmark. While the company's 10-year median is 27.20 vs. the industry median of 9.99, Creative Medical Technology Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 9.99, based on 1,425 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creative Medical Technology Holdings's current WACC % of 9.21% is 7.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Creative Medical Technology Holdings and its competitors. For the Biotechnology industry, the median WACC % is 9.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creative Medical Technology Holdings's current WACC % is 9.21%, which is 66% below median its own 10-year median of 27.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $0.81 — trading 153.2% above its estimated fair value. The current WACC % is 9.21%, which is 66% below median its 10-year median of 27.20 and 7.8% below the Biotechnology industry median of 9.99. Creative Medical Technology Holdings' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current WACC % is 9.21% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?

Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued. The current stock price of $0.81 is trading 153.2% above its estimated GF Value™ of $0.32. GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.

Key valuation signals for CELZ:

  • WACC %: 9.21% (66% below median its 10-year median of 27.20)
  • GF Value™: $0.32 vs. price of $0.81 (153.2% above fair value)
  • GF Score™: 34/100 with 4 warning signs
  • Industry Position: 7.8% below the Biotechnology median (#627 of 1425)

No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Creative Medical Technology Holdings Business Description

Address 211 E Osborn Road, Phoenix, AZ, USA, 85012
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
34GF Score

Get the complete analysis for CELZ

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.81
Price
$0.32
GF Value